C4 Therapeutics announced Phase 1 trial data for cemsidomide in multiple myeloma, presented at the IMS Annual Meeting on September 20.
Quiver AI Summary
C4 Therapeutics, a clinical-stage biopharmaceutical company focusing on targeted protein degradation, announced that it will present data from its Phase 1 clinical trial of cemsidomide for multiple myeloma at the International Myeloma Society Annual Meeting on September 20, 2025. The oral presentation will detail the trial's safety and efficacy results, showcasing the drug's well-tolerated profile and promising response rates in patients with relapsed/refractory multiple myeloma when combined with dexamethasone. C4T has completed patient enrollment and dose escalation, and will also hold an investor webcast on the same day to discuss these findings and future clinical development plans. Cemsidomide is designed to target specific transcription factors involved in myeloma and is noted for its potential to improve patient outcomes by effectively degrading disease-causing proteins.
Potential Positives
- Data from C4T's Phase 1 clinical trial of cemsidomide will be presented at a prominent international conference, increasing visibility and credibility in the oncology community.
- The trial continues to demonstrate a well-tolerated safety profile and compelling response rates, suggesting potential for positive outcomes in treatment for multiple myeloma.
- C4T is utilizing its TORPEDO® platform to advance targeted oncology programs, indicating innovation and a strategic approach to drug development.
Potential Negatives
- Potential over-reliance on forthcoming data from the Phase 1 trial could leave investors and stakeholders concerned about the long-term viability and success of cemsidomide.
- Presentation of trial results at an upcoming meeting suggests that the company has not yet finalized or published data on cemsidomide, which may raise questions about progress and urgency in their clinical development timeline.
- Holding the investor webcast after the presentation indicates that the company may be facing transparency issues, as stakeholders may prefer more immediate access to results rather than waiting for a delayed webcast.
FAQ
What is the purpose of the Phase 1 trial of cemsidomide?
The trial aims to assess the safety and efficacy of cemsidomide in treating multiple myeloma.
When will the results of the cemsidomide trial be presented?
The results will be shared on September 20, 2025, at the IMS Annual Meeting in Toronto, Canada.
Who will present the cemsidomide trial results?
Binod Dhakal, M.D., from the Medical College of Wisconsin, will present the findings.
How can investors access the C4T webcast?
Investors can access the webcast on September 20, 2025, through C4T's website or the Events & Presentations page.
What is cemsidomide's mechanism of action?
Cemsidomide is designed to selectively degrade IKZF1/3, which are key drivers in multiple myeloma and non-Hodgkin’s lymphoma.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$CCCC Hedge Fund Activity
We have seen 57 institutional investors add shares of $CCCC stock to their portfolio, and 87 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- RA CAPITAL MANAGEMENT, L.P. removed 4,878,000 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $7,804,800
- BLACKROCK, INC. removed 3,455,799 shares (-65.4%) from their portfolio in Q2 2025, for an estimated $4,941,792
- SAMLYN CAPITAL, LLC removed 3,015,139 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $4,311,648
- ADAGE CAPITAL PARTNERS GP, L.L.C. removed 1,350,000 shares (-87.1%) from their portfolio in Q2 2025, for an estimated $1,930,500
- ARROWMARK COLORADO HOLDINGS LLC removed 1,082,207 shares (-84.1%) from their portfolio in Q2 2025, for an estimated $1,547,556
- MILLENNIUM MANAGEMENT LLC added 1,035,445 shares (+1571.3%) to their portfolio in Q2 2025, for an estimated $1,480,686
- STATE STREET CORP removed 937,045 shares (-76.5%) from their portfolio in Q2 2025, for an estimated $1,339,974
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
WATERTOWN, Mass., Sept. 03, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that data from its Phase 1 dose escalation clinical trial of cemsidomide in multiple myeloma (MM) will be shared in an oral presentation at the International Myeloma Society (IMS) Annual Meeting on September 20, 2025 at 11:10 am ET in Toronto, Canada.
IMS Annual Meeting 2025 Oral Presentation
Title
: Updated Results of a Phase 1 First-in-Human Study of Cemsidomide (CFT7455), a Novel MonoDAC
®
Degrader, with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
Presentation Date and Time
: Saturday, September 20, 2025 at 11:10 am ET
Session
: Future Targets and New Modalities of Therapy
Location
: Metro Toronto Convention Centre - South Building, Room 701
Presenter
: Binod Dhakal, M.D., M.S., associate professor of medicine, Medical College of Wisconsin, Division of Hematology
C4T has completed enrollment and dose escalation for its Phase 1 trial of cemsidomide in MM, which continues to demonstrate a well-tolerated safety profile and compelling response rates. The presentation at the IMS Annual Meeting will include data from all safety and efficacy evaluable MM patients from all dose levels studied in the cemsidomide with dexamethasone cohort in the Phase 1 trial. C4T’s investor webcast will highlight the data from the oral presentation at the IMS Annual Meeting and provide additional detail on the company’s planned next steps of clinical development.
C4T Investor Webcast
C4T will host a webcast on September 20, 2025 at 3 pm ET. To join the webcast, please visit this
link
or the “Events & Presentations” page of the Investors section on the company’s website at
www.c4therapeutics.com
. A replay of the webcast will be archived and available following the event. Additionally, following the oral presentation at the IMS Annual Meeting, C4T will share that presentation on its website under the
Scientific Presentations and Publications page
.
About C4 Therapeutics
C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO
®
platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T’s degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. For more information, please visit
www.c4therapeutics.com
.
About Cemsidomide
Cemsidomide is an investigational, orally bioavailable small-molecule degrader designed to be a more potent and selective degrader of IKZF1/3, transcription factors that drive multiple myeloma (MM) and non-Hodgkin’s lymphomas (NHL), with unique pharmacokinetic properties. Clinical data has shown that cemsidomide is well-tolerated. In MM, cemsidomide displays compelling evidence of anti-myeloma activity and immunomodulatory effects. More information may be accessed at www.clinicaltrials.gov (identifier: NCT04756726).
Contacts:
Investors:
Courtney Solberg
Associate Director, Investor Relations
[email protected]
Media:
Loraine Spreen
Senior Director, Corporate Communications & Patient Advocacy
[email protected]
